This emerging technology harnesses small molecules to induce highly specific elimination of disease-causing proteins. These molecules, functioning as “molecular bridges,” link a target protein to the cellular machinery responsible for protein degradation. This bridging mechanism allows for the targeted removal of proteins previously considered “undruggable” by traditional methods that typically inhibit protein function rather than eliminate the protein itself. For example, a bivalent molecule can be designed with one arm that binds to a specific protein targeted for degradation, and another arm that recruits an E3 ubiquitin ligase, a key component of the protein degradation system.
The ability to selectively eliminate proteins opens exciting new avenues for therapeutic intervention. This approach offers potential advantages over traditional drug modalities by addressing the root cause of diseases driven by problematic proteins, rather than just mitigating their effects. Historically, drug development has focused on inhibiting the function of disease-related proteins. However, many proteins lack suitable binding sites for effective inhibition. This new degradation technology overcomes this limitation, vastly expanding the range of potentially druggable targets and offering new hope for diseases currently lacking effective treatments.
